Sustained improved survival of patients with metastatic melanoma after the introduction of anti-PD-1-based therapies-Reference-Cited by-同舟云学术

Sustained improved survival of patients with metastatic melanoma after the introduction of anti-PD-1-based therapies

Published:2023-12 Issue: Volume:195 Page:113392
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Schina Aimilia,Pedersen Sidsel^ORCID,Spenning Anne-Louise,Laursen Olivia Kaas,Pedersen Cecilia,Haslund Charlotte Aaquist,Schmidt Henrik,Bastholt Lars^ORCID,Svane Inge Marie,Ellebaek Eva^ORCID,Donia Marco^ORCID

Funder

Københavns Universitet

Danish Council for Independent Research

Else og Mogens Wedell Wedellsborgs Fond

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. Overall survival, progression-free survival, and tumor response benefit supporting initial US Food and Drug Administration approval and indication extension of new cancer drugs, 2003-2021;Michaeli;J Clin Oncol,2022

2. Real-world evidence in oncology: opportunities and limitations;Di Maio;Oncologist,2020

3. The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials;Donia;Eur J Cancer,2017

4. Sorafenib effectiveness in advanced hepatocellular carcinoma;Sanoff;Oncologist,2016

5. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet,2012

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study;European Journal of Cancer;2024-07

2. Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for Early Identification of Checkpoint-Inhibitor-Induced Pseudoprogression;Cancers;2024-02-27